Later, it was found that FXR could inhibit the proliferation of the prostate cancer cell line LNcaP through the upregulation of the tumor suppressor PTEN and the suppression of lipid metabolism by targeting sterol response element binding protein 1 (SREBP1) [141,142]. Here, NR1H4 is linked to prostate carcinoma.